Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Methicillin-Resistant Staphylococcus Aureus Infections – Epidemiology – Europe Data

Login to access report north_east
Contact sales account_box

Methicillin-Resistant Staphylococcus aureus Epidemiology

DRG Epidemiology’s coverage of methicillin-resistant staphylococcus aureus comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the incidence of methicillin-resistant staphylococcus aureus for each country, as well as annualized case counts projected to the national population.

DRG Epidemiology’s methicillin-resistant staphylococcus aureus forecast will answer the following questions:

How will changes in the levels of exposure to known risk or protective factors affect the number of methicillin-resistant staphylococcus aureus events per year?

Of all people diagnosed with methicillin-resistant staphylococcus aureus, how many in each country across the major mature pharmaceutical markets are drug-treated?

How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of methicillin-resistant staphylococcus aureus over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

DRG Epidemiology provides at least ten years of forecast data for the following methicillin-resistant staphylococcus aureus patient populations:

Diagnosed MRSA Events by Treatment

Methicillin-Resistant Staphylococcus aureus Diagnosed MRSA Events

Methicillin-Resistant Staphylococcus aureus Diagnosed MRSA Events – BSI

Methicillin-Resistant Staphylococcus aureus Diagnosed MRSA Events – cIAI

Methicillin-Resistant Staphylococcus aureus Diagnosed MRSA Events – cSSSI

Methicillin-Resistant Staphylococcus aureus Diagnosed MRSA Events – HAP

Methicillin-Resistant Staphylococcus aureus Diagnosed MRSA Events – HCAP

Methicillin-Resistant Staphylococcus aureus Diagnosed MRSA Events – Nosocomial Pneumonia

Methicillin-Resistant Staphylococcus aureus Diagnosed MRSA Events – SSI

… and more (details available on request).

Note: coverage may vary by country and region.

Table of contents

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east